The 13th International RSV Symposium, this year hosted in Iguazu Falls, Brazil, is a 4-day scientific programme centred around the latest research on RSV and other respiratory viruses.
Andrew Catchpole, our Chief Scientific Officer will be presenting “Disease Characteristics and Immunological Profiles Obtained from a Pilot Study in a Newly Developed hMPV Human Challenge Model” on Saturday 15th March at 09:45.
And our Senior Study Physician Alexandre Lima, will be presenting a poster titled "Incidental Myocarditis in Healthy Adults Following RSV Inoculation: Insights from a Decade of Controlled Human Infection Studies".
As the world leader in human challenge trials, hVIVO has vast experience investigating RSV infection, having inoculated almost 2000 participants with RSV-A or RSV-B. hVIVO has the only commercially available RSV challenge model, which has already accelerated the development of several vaccines/antivirals by avoiding the risks and pitfalls of expensive large-scale field studies.
A recent paper published in the New England Journal of Medicine and co-authored by hVIVO’s Andrew Catchpole and Alex Mann, highlighted favourable results in a Phase 2a vaccine study using our RSV challenge model. We also announced positive results in October 2024 and February 2025 for 2 antiviral products tested using the same model.
In January 2025, we successfully completed our pilot hMPV characterisation study, which showed good infectivity rates and clear symptoms in inoculated participants. Andrew Catchpole will be presenting the findings at the 13th RSV Symposium, but you can also see him discussing the results and hMPV challenge model in more detail here.
The final stages of our hMPV characterisation study are scheduled to complete in H1 2025, and we will be ready to run trials investigating vaccines and antivirals targeting hMPV from H2 2025.
Our RSV and hMPV challenge models were made possible by our cutting-edge 50-bed quarantine facility in London and hLAB, our integrated specialist virology and immunology laboratory. hLAB has developed and validated quantitative RSV and hMPV qRT-PCR, viral culture, and serology antibody assays, which are ready for use in hVIVO’s challenge and field studies.
hLAB also offers standalone laboratory services for studies performed at other sites. See how hLAB supported a global RSV development programme involving 5 field studies across 82 sites, and how the process was enhanced using hVIVO’s proprietary Stabilisation Transport Matrix.
Presented by Dr Andrew Catchpole, Chief Scientific Officer, hVIVO
13th International RSV Symposium,
Iguazu Falls, Brazil,
12-15 March 2025
